Neuropathic pain is the sensation of pain due to abnormal discharges of impaired or injured neural structures in the peripheral &/or central nervous system.
It is characterized by hyperesthesia, hyperalgesia and allodynia.
Common neuropathic pain syndromes are central neuropathic pain, painful diabetic peripheral neuropathy, postherpetic neuralgia, trigeminal neuralgia, postsurgical neuropathic pain, HIV-related neuropathy, lumbosacral radiculopathy and complex regional pain syndrome.
New drug applications approved by US FDA as of 1 - 15 October 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Capsaicin 8% patch shows potential as a long-term treatment option for non-diabetic patients with peripheral neuropathic pain, with a new study reporting that repeat treatment over 52 weeks is well tolerated, producing sustained reductions in average pain intensity with variable sensory function alteration and minimal chance of complete sensory loss.
Early detection, intervention and adoption of a healthy lifestyle are the key to ending dementia, according to Professor Vincent Mok of the Division of Neurology, Faculty of Medicine, Chinese University of Hong Kong.